Merrill et al. SLEek LTE. ABBV-599 (Elsubrutinib and Upadacitinib Combination) and Upadacitinib monotherapy in SLE. 104
Tweet Content
Merrill et al. SLEek LTE. ABBV-599 (Elsubrutinib and Upadacitinib Combination) and Upadacitinib monotherapy in SLE. 104 week data. SRI-4 85.4%, 82.1%, and 61.3% in the ABBV-599 HD, UPA 30 mg, and PBO to ABBV-599 HD group @RheumNow #ACR24 Abstr#2577 https://t.co/wc6Mb13U4O https://t.co/Xu1pMhAUrG
Links
Efficacy and Safety of ABBV-599 (Elsubrutinib and Upadacitinib Combination) and…
https://acrabstracts.org/abstract/efficacy-and-safety-of-abbv-599-elsubrutinib-…
Show on Archive Page
On
Display in Search Results
On
PDQ
Off